• Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Careers
  • Tools
Finnegan
    • AIA Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • IP FDA Blog
    • Prosecution First Blog
  • Articles
  • IP Updates
  • Podcasts
  • Events
  • Webinars
  • Books

AIA Blog

New PTAB Final Rule Places Burden on Patent Owner to Show Motion to Amend Complies with Statutory and Regulatory Requirements

December 21, 2020

By Trenton A. Ward

Edited by Kevin D. Rodkey

On December 21, 2020, the USPTO published its final rule allocating the burdens of persuasion for motions to amend and the patentability of proposed substitute claims in IPR, PGR, and CBM proceedings.  This rule package follows up on the USPTO’s notice of proposed rulemaking released in October 2019.  This rule largely codifies the existing practice and the Federal Circuit’s precedent in Aqua Products and other decisions regarding motions to amend in AIA trials.

Specifically, the final rule “assigns the burden of persuasion to the patent owner to show … that a motion to amend complies with certain statutory and regulatory requirements for a motion to amend.”  85 Fed. Reg. 82923, 82924 (Dec. 21, 2020).  For example, a Patent Owner bears the burden to show that proposed substitute claims comply with statutory requirements and regulatory requirements, such as responding to a ground of unpatentability involved in the trial and not seeking to enlarge the scope of the claims.  On the other hand, the final rule, however, “assigns the burden of persuasion to the petitioner to show … that any proposed substitute claims are unpatentable.”  Id. 

As to independent action by the Board, the final rule also provides that “the Board may, in the interests of justice, exercise its discretion to grant or deny a motion to amend, but only for reasons supported by readily identifiable and persuasive evidence of record in the proceeding.”  Id.  In exercising its discretion, the Board may make of record readily identifiable and persuasive evidence in a related proceeding before the Office or evidence that a district court can judicially notice.  The Office stated that it anticipates that the Board will exercise its discretion in “only in rare circumstances.”  Id.

These final rules will be effective on January 20, 2021.  Thus, these new rules will apply to all motions to amend filed on or after January 20, 2021.

Tags

Patent Trial and Appeal Board (PTAB), United States Patent and Trademark Office (USPTO)

Related Practices

Post-Grant Proceedings

IPR, PGR, and CBM

Contacts

Trenton_Ward
Trenton A. Ward
Partner
Atlanta, GA
+1 404 653 6441
Email
Kevin_Rodkey
Kevin D. Rodkey
Partner
Atlanta, GA
+1 404 653 6484
Email

Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

Best Practices in Intellectual Property 2021

June 14-15, 2021

Tel Aviv

Webinar

Patent Law Institute 2021: Critical Issues & Best Practices

April 29-30, 2021

Webinar

Webinar

Patent Law Institute 2021: Critical Issues & Best Practices

April 1-2, 2021

Webinar

Seminar

FORUM!Live: Patent Claim Construction

March 24-25, 2021

Virtual

Webinar

Litigation Holds: Creating Effective Notices, Implementing Efficient Collection Processes, Protecting Privilege

March 17, 2021

Webinar

Webinar

Patent Claim and Specification Drafting and Prosecution

March 11, 2021

Webinar

Webinar

Patent Year in Review: Key Decisions, Trends, and Strategies

February 25, 2021

Webinar

Conference

Pharma & Biotech Patent Litigation in Europe

February 23-25, 2021

Virtual

Conference

Symposium: Navigating and Rectifying the Design Patent Muddle

February 19, 2021

Virtual

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

  • Privacy
  • Disclaimer
  • EEO Statement

© 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP